Huvy, founded in late 2021 by Léonie Schroder and Bryan Boulé, develops an artificial intelligence platform designed for primary healthcare professionals to improve the early detection of melanoma and streamline patient care pathways. The project originated from a delayed diagnosis involving someone close to the co-founder, alongside a shared observation: delays in accessing dermatologists lead to compromised patient outcomes.
Co-designed with healthcare providers, the solution is tailored to real-world clinical constraints: ease of use, rapid processing (results delivered in under 10 seconds), robustness against image artifacts, and transparent outputs. Huvy positions itself as a clinical referral tool integrated into the care pathway, not as a replacement for the specialist.
The company highlights obtaining CE mark Class IIb as a foundational milestone, attesting to its clinical and regulatory rigor. It addresses a major public health challenge: 50% of patients abandon dermatological care deemed overly complex or inaccessible.
Supported by the La Rochelle technology park since 2022, Huvy has structured its development through a local innovation ecosystem. The next milestones include real-world regional deployment, followed by a new funding round to accelerate larger-scale expansion.




